Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhancing Immunity to Malaria in Young Children With Effective Chemoprevention
NCT04978272Phase 3Active, not recruiting
- Start
- Feb 2022
- Primary completion
- May 2027
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dihydroartemisinin + piperaquine in malaria (3 arms). Primary endpoint: Incidence of symptomatic malaria following cessation of IPTc. Started Feb 2022; status: active, not recruiting.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04978272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978272.